Arvinas, a biotech company specializing in targeted protein degradation therapies, will announce its first quarter 2026 financial results on May 12, 2026. The company will provide a corporate update via a live webcast accessible on its investor website. Arvinas recently gained FDA approval for VEPPANU, the first PROTAC drug for advanced breast cancer, and is advancing several other drug candidates in clinical trials. This update will offer insights into their financial health and progress in drug development.
Cyclr's benchmark study reveals that using a task-focused 'Thin MCP' server design can reduce AI token consumption by about 75% compared to a broad 'Thick MCP' design, while maintaining the same level of answer accuracy. The study tested configuratio...
Xcel Brands has signed a licensing agreement with KBL Group to produce ready-to-wear collections for OFF/DUTY by Coco Rocha, a fashion brand created with supermodel Coco Rocha. KBL Group will handle sourcing, product development, manufacturing, and s...
State Street Global Advisors & Affiliates disclosed an increase in their holdings of DCC plc ordinary shares to 1,194,093 shares, representing approximately 1.398% of the company. The purchases occurred on July 3, 2026, at a price of €60.90 per share...
Bath & Body Works introduced Fruit Fusion, a new body care franchise featuring fruit-inspired scents and hydrating formulas, available in the U.S. and Canada starting July 6, 2026. Actress Hilary Duff serves as the brand ambassador and creative partn...
The 32nd Global Family Office Investment Summit in Lake Como gathered over 200 family office leaders, investors, and entrepreneurs from 27 countries to discuss emerging trends in AI, private equity, healthcare innovation, and global investment opport...
